Copy to clipboard 
Generex Biotechnology entered into a letter of intent (LOI) to acquire Pantheon Medical – Foot & Ankle, manufacturer of the FDA-cleared Balanced Plating System, for US $1.4MM in Generex stock, plus additional cash and stock consideration upon completion of sales and profit milestones. The transaction is expected to close in coming weeks.
Terms include all assets of Pantheon (e.g. business operations, accounts receivable and inventory, contracts and an FDA letter related to the balanced plating system). The company’s “all-in-one” integrated kit includes plates, screws and tools for foot/ankle procedures. Over the next three years, Pantheon will submit new lines to FDA including cannulated screws and staples, as well as a proprietary hammertoe system.
Additionally, Generex signed an LOI to acquire Medisource Partners for $1MM in stock plus potential milestone payments. Medisource is contracted with over 25 vendors (including Pantheon Medical) for U.S. distribution of implants and devices for spine, hips, knees, foot, ankle, hand and wrist surgeries.
Generex describes itself as an integrated healthcare holding company providing support to physicians, including orthopaedic surgeons, through a Management Services Organization network (MSO). This acquisition represents the company’s entry into the surgical field; a wholly-owned distribution subsidiary integrates the MSO with a pharmacy network, clinical diagnostic lab, durable medical equipment company and a call center call center focused on patient education and satisfaction.
Source: Generex Biotechnology Corp.
Generex Biotechnology entered into a letter of intent (LOI) to acquire Pantheon Medical – Foot & Ankle, manufacturer of the FDA-cleared Balanced Plating System, for US $1.4MM in Generex stock, plus additional cash and stock consideration upon completion of sales and profit milestones. The transaction is expected to close in coming weeks.
...
Generex Biotechnology entered into a letter of intent (LOI) to acquire Pantheon Medical – Foot & Ankle, manufacturer of the FDA-cleared Balanced Plating System, for US $1.4MM in Generex stock, plus additional cash and stock consideration upon completion of sales and profit milestones. The transaction is expected to close in coming weeks.
Terms include all assets of Pantheon (e.g. business operations, accounts receivable and inventory, contracts and an FDA letter related to the balanced plating system). The company’s “all-in-one” integrated kit includes plates, screws and tools for foot/ankle procedures. Over the next three years, Pantheon will submit new lines to FDA including cannulated screws and staples, as well as a proprietary hammertoe system.
Additionally, Generex signed an LOI to acquire Medisource Partners for $1MM in stock plus potential milestone payments. Medisource is contracted with over 25 vendors (including Pantheon Medical) for U.S. distribution of implants and devices for spine, hips, knees, foot, ankle, hand and wrist surgeries.
Generex describes itself as an integrated healthcare holding company providing support to physicians, including orthopaedic surgeons, through a Management Services Organization network (MSO). This acquisition represents the company’s entry into the surgical field; a wholly-owned distribution subsidiary integrates the MSO with a pharmacy network, clinical diagnostic lab, durable medical equipment company and a call center call center focused on patient education and satisfaction.
Source: Generex Biotechnology Corp.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
